DNDi, Abbott sign joint research, non-exclusive licensing agreement

The neglected tropical diseases include Chagas disease, helminth infections, leishmaniasis and sleeping sickness.

Under the collaboration, DNDi and Abbott scientists will focus initial efforts on discovering and advancing novel antimicrobial agents with activity against these neglected diseases.

Under the agreement, Abbott has the right of first negotiation to become DNDi’s development and distribution partner.

DNDi is free to engage other partners if Abbott chooses not to serve as a development and distribution partner.

Both DNDi and Abbott share their unique scientific expertise and resources to advance the development of drugs adapted to patient needs.

DNDi gains access to Abbott compounds, data and information to accelerate drug development.

Any resulting products will be provided in endemic countries at the lowest sustainable price to expand patient access.

DNDi executive director Bernard Pecoul said Abbott has demonstrated a great level of commitment by partnering with DNDi to share not only its compounds, but also its expertise and resources.